Tadalafil Tablet
Product Images NDC 68788-4018

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68788-4018). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil Tab 5mg (20mg Dahej 30s)

Not available.*

FDA Label Image

Structural Formula (30ee4705 36a5 4a56 852d 9d76c40668db 01)

FDA Label Image

Figure 1 (30ee4705 36a5 4a56 852d 9d76c40668db 02)

FDA Label Image

Figure 2 (30ee4705 36a5 4a56 852d 9d76c40668db 03)

This data appears to be related to a study or evaluation involving standing and supine systolic blood pressure (BP) measurements over time after the administration of Tadalafil 20 mg & doxazosin 8 mg and Placebo & doxazosin 8 mg. The chart shows the variation in systolic BP in mmHg over 24 hours post-dose. The study seems to compare the effects of different medication combinations on blood pressure.*

FDA Label Image

Figure 3 (30ee4705 36a5 4a56 852d 9d76c40668db 04)

FDA Label Image

Figure 4 (30ee4705 36a5 4a56 852d 9d76c40668db 05)

This is a data table showing plasma Tadalafil concentrations in ug/L at different time intervals after taking a single 20-mg Tadalafil dose, a single 5-mg Tadalafil dose, and a once-daily 5-mg Tadalafil dose following 5 consecutive days of administration. The time intervals include measurements at 0, 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 hours.*

FDA Label Image

Figure 5 (30ee4705 36a5 4a56 852d 9d76c40668db 06)

Change from Baseline in IPSS Total Score compared between Tadalafil 5 mg and Placebo group over a 12-week treatment period.*

FDA Label Image

Figure 6 (30ee4705 36a5 4a56 852d 9d76c40668db 07)

Change from Baseline in IPSS Total Score comparing Tadalafil 5 mg with Placebo over a period of 4, 8, and 12 weeks of treatment. The statistical significance of the results is denoted by *p<0.001.*

FDA Label Image

Figure 7 (30ee4705 36a5 4a56 852d 9d76c40668db 08)

This text appears to be showing the LS Mean Change from Baseline for a study comparing Tadalafil/Finasteride and Placebo/Finasteride at 12 and 26 weeks of therapy. The data also includes p-values for the comparison.*

FDA Label Image

Figure 8 (30ee4705 36a5 4a56 852d 9d76c40668db 09)

This text provides information on the change from baseline in IPSS Total Score comparing Tadalafil 5mg to Placebo over a 12-week treatment duration. The result indicates a statistically significant difference between the two groups with p<0.01, suggesting that Tadalafil 5mg had a positive impact on the IPSS Total Score compared to Placebo.*

FDA Label Image

Torrent Logo (30ee4705 36a5 4a56 852d 9d76c40668db 10)

FDA Label Image

Torrent Logo-pi (30ee4705 36a5 4a56 852d 9d76c40668db 11)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.